ORLANDO, Fla--8 Nov--PRNewswire-AsiaNet/InfoQuest - Data Presented at AHA Scientific Sessions Adds to Body of Evidence Highlighting Unique Benefits of CRESTOR Across the Spectrum of Atherosclerosis Disease Progression New analysis of the METEOR (Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin) trial presented today showed CRESTOR(TM) (rosuvastatin) 40mg slowed the progression of carotid intima-media thickness (CIMT) in patients at varying levels of risk for cardiovascular disease while all placebo treated subjects exhibited significantly higher progression rates. This new analysis was conducted in subjects defined by the Framingham risk assessment tool as having less than two or two or more risk factors (RF) with either thinner or thicker CIMT (